apatinib + camrelizumab + eribulin

This is a combination regimen of three drugs—apatinib, camrelizumab, and eribulin—used in the treatment of advanced triple-negative breast cancer (TNBC), particularly in patients who have been heavily pretreated. - **Apatinib** is a small molecule tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking angiogenesis and reducing tumor blood supply. - **Camrelizumab** is a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1), functioning as an immune checkpoint inhibitor to enhance anti-tumor immune responses. - **Eribulin** is a synthetic analog of halichondrin B that acts as an antimitotic agent by inhibiting microtubule dynamics, leading to mitotic arrest and apoptosis in cancer cells. The combination has shown promising efficacy with manageable safety in phase II and ongoing phase III clinical trials for advanced TNBC, with objective response rates around 37% and median progression-free survival near 8 months[1][3][4][5][7]. The regimen leverages antiangiogenic effects from apatinib, immunomodulation from camrelizumab, and cytotoxicity from eribulin.

Other names

apatinib + camrelizumab + eribulin